Article

OBJECTIVE: To investigate the use of rimabotulinumtoxinB (BoNT/B [Myobloc])
compared with placebo in treating hyperhidrosis in the residual limbs of
individuals with amputation. DESIGN: Randomized, double-blind, placebo-controlled
pilot study. SETTING: Military medical center. PARTICIPANTS: Male participants
(N=9) with 11 major amputations of the lower limbs and who complained of
excessive sweating in their residual limbs were enrolled in the study between
September 24, 2008 to October 28, 2011. Participants' lower limbs were randomly
assigned to receive injections of either BoNT/B (n=7) or placebo (n=4).
INTERVENTION: BoNT/B. MAIN OUTCOME MEASURES: The primary efficacy variable was a
minimum of 50% reduction in sweat production 4 weeks after the injection as
measured via gravimetric sweat analysis after 10 minutes of physical exertion.
Secondary analyses were performed on prosthetic function and pain. RESULTS: All
volunteers (100%; 7) in the BoNT/B group achieved a minimum of 50% reduction in
sweat production as compared with only 50% (2) in the placebo group. The percent
reduction was significantly greater for the BoNT/B group than for the placebo
group (-72.7%+/-15.7% vs -32.7%+/-39.2%; P<.05). Although both groups
subjectively self-reported significant sweat reduction and improved prosthetic
function (P<.05 for both), objective gravimetric sweat analyses significantly
decreased only for the BoNT/B group (2.3+/-2.3g vs 0.7+/-1.1g; P<.05). Neither
group reported a change in phantom limb pain or residual limb pain (P>.05 for both). CONCLUSIONS: BoNT/B successfully reduces sweat production in individuals
with residual limb hyperhidrosis, but does not affect pain. No differences were
found in perceived effect on prosthetic use between BoNT/B and placebo groups.
CI - Copyright (c) 2016 American Congress of Rehabilitation Medicine. Published by
Elsevier Inc. All rights reserved.

Langue : ANGLAIS